REHOVOT, Israel, Oct. 4 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today that a Phase II Eastern European based clinical trial for its proprietary lead development compound MTR106 (tablet formulation of MTR104), a low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications, is progressing on schedule for completion by the end of calendar 2006.
This Phase II, randomized double blind, placebo-controlled dose-escalating GCP study, will assess efficacy, pharmacokinetics and pharmacodynamics of MTR106 tablets during the treatment of acute migraine attacks without aura in females.
To assess safety, preliminary efficacy, tolerability, and the pharmacokinetic parameters of MTR106 tablets, the product is being administered in four escalating doses to females suffering from migraine without aura. The primary clinical endpoints are to reduce the intensity of migraine pain within 2 hours post treatment and to demonstrate the absence of drug-related adverse events.
Meditor Pharmaceuticals Ltd. is an Israel-based pharmaceutical development company founded to develop and commercialize a class of small organic synthetic molecules with profound cardiovascular pharmacologic activity. The lead development compound is MTR104, a low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications. Meditor's patent portfolio provides the company with a strong proprietary position in the U.S. and worldwide. For more information on the company and its drug development activities, please visit www.meditorpharma.com
Meditor Pharmaceuticals Ltd. is continuing with the development of its lead compound while currently seeking offers from pharmaceutical manufacturers having the potential to develop, register and commercialize MTR106. For all inquiries please contact Michael Schultz, R.Ph., VCG & Associates, Inc. at 636-329-1452 or Dr. David Coffin-Beach at 416-725-3956.
Meditor Pharmaceuticals Ltd.
CONTACT: Michael Schultz, R.Ph., of VCG & Associates, Inc.,+1-636-329-1452; or Dr. David Coffin-Beach, +1-416-725-3956, both forMeditor Pharmaceuticals Ltd.